Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2

Autor: Wael Bahnan, Sebastian Wrighton, Martin Sundwall, Anna Bläckberg, Olivia Larsson, Urban Höglund, Hamed Khakzad, Magdalena Godzwon, Maria Walle, Elisabeth Elder, Anna Söderlund Strand, Lotta Happonen, Oscar André, Johannes Kumra Ahnlide, Thomas Hellmark, Vidar Wendel-Hansen, Robert PA. Wallin, Johan Malmstöm, Lars Malmström, Mats Ohlin, Magnus Rasmussen, Pontus Nordenfelt

Publikováno v: Frontiers in Immunology, Vol 12 (2022)

Spike-specific antibodies are central to effective COVID19 immunity. Research efforts have focused on antibodies that neutralize the ACE2-Spike interaction but not on non-neutralizing antibodies. Antibody-dependent phagocytosis is an immune mechanism

Externí odkaz: https://doaj.org/article/f92905abfadc4d269db7f2ae1d052963

Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2

Autor: Wael, Bahnan, Sebastian, Wrighton, Martin, Sundwall, Anna, Bläckberg, Olivia, Larsson, Urban, Höglund, Hamed, Khakzad, Magdalena, Godzwon, Maria, Walle, Elisabeth, Elder, Anna Söderlund, Strand, Lotta, Happonen, Oscar, André, Johannes Kumra, Ahnlide, Thomas, Hellmark, Vidar, Wendel-Hansen, Robert Pa, Wallin, Johan, Malmstöm, Lars, Malmström, Mats, Ohlin, Magnus, Rasmussen, Pontus, Nordenfelt

Publikováno v: Frontiers in Immunology

Spike-specific antibodies are central to effective COVID19 immunity. Research efforts have focused on antibodies that neutralize the ACE2-Spike interaction but not on non-neutralizing antibodies. Antibody-dependent phagocytosis is an immune mechanism

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ed36399e36867a337e46cd156a212c66
https://pubmed.ncbi.nlm.nih.gov/35095897

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial

Autor: Ingebjørg Baksaas, Gerd Fätkenheuer, Giuseppe Pantaleo, Jürgen K. Rockstroh, Barry Peters, Graeme Moyle, W. David Hardy, Jan van Lunzen, Andreas Plettenberg, Adriano Lazzarin, Margaret A. Fischl, Babafemi Taiwo, Birger Sørensen, Kim Ellefsen, Richard B. Pollard, Ronald T. Mitsuyasu, Stefan Persson, Arnt-Ove Hovden, Darren Jolliffe, Bonaventura Clotet, Øyvind Jelmert, Maja A. Sommerfelt, Keikawus Arastéh, Dirk Schürmann, Felipe García, Vidar Wendel-Hansen, Martin Fisher, Daniel Podzamczer, David M. Asmuth

Publikováno v: Pollard, RB; Rockstroh, JK; Pantaleo, G; Asmuth, DM; Peters, B; Lazzarin, A; et al.(2014). Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: A phase 2 randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases, 14(4), 291-300. doi: 10.1016/S1473-3099(13)70343-8. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/2r859753
The Lancet. Infectious diseases, vol 14, iss 4

Background: Present combination antiretroviral therapy (cART) alone does not cure HIV infection and requires lifelong drug treatment. The potential role of HIV therapeutic vaccines as part of an HIV cure is under consideration. Our aim was to assess

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7797c28f047ea48cbaff67fe00c2df6
https://pubmed.ncbi.nlm.nih.gov/24525315

Cell phenotype (CD23)-dependent variation in EBV genome copy numbers within lymphoblastoid cell lines (LCL)

Autor: Vidar Wendel-Hansen, George Klein, Mats Ericson, Anders Rosén, Wen Tao

Publikováno v: International Journal of Cancer. 50:589-592

Three Epstein-Barr-virus-transformed lymphoblastoid cell lines (LCL) were analysed on the basis of their CD23 expression. Levels of EBV-DNA were compared in the positive and negative subpopulations. Two lines were further analysed with regard to EBNA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8af493e851d57bbcd3a21de495c8c2a8
https://doi.org/10.1002/ijc.2910500417

The gene encoding CD23 leukocyte antigen (FCE2) is located on human chromosome 19

Autor: Göran Levan, Vidar Wendel-Hansen, Claude Szpirer, Irma Jansson, M. Quamrul Islam, George Klein, Michèle Riviere, Masatsune Uno, Junji Yodoi, Anders Rosén, Josiane Szpirer

Publikováno v: ResearcherID

Using Southern blot analysis of DNAs from human×rodent cell hybrids, we have mapped the CD23 leukocyte antigen gene (FCE2) to human chromosome 19.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde29b68b6570a2f01a0098ef39c3d2e
https://pubmed.ncbi.nlm.nih.gov/2141728